loader image
Sunday, December 21, 2025
74.1 F
McAllen
- Advertisement -

From Mild Cognitive Impairment to Alzheimer’s 

Translate to Spanish or other 102 languages!

How can we predict who will progress to Alzheimer’s from mild cognitive impairment. Image for illustration purposes
How can we predict who will progress to Alzheimer’s from mild cognitive impairment. Image for illustration purposes

Medical News Today

- Advertisement -
  • Dementia affects more than 55 million people worldwide, costing around $1.3 trillion per year.
  • The most common form of dementia, Alzheimer’s disease, affects up to 70% of these people.
  • New treatments are most effective if started early in the progression of the disease, but diagnosis is difficult at this stage as early symptoms are often dismissed as normal changes due to aging.
  • Now, a new study has developed a deep learning framework that can identify the risk of progressing from mild cognitive impairment to Alzheimer’s.

In 2019, according to the Global Burden of Diseases, Injuries, and Risk Factors StudyTrusted Source, an estimated 57.4 million people worldwide had dementia.

Follow the link below to read the entire article on Medical News Today: 

https://www.medicalnewstoday.com/articles/from-mild-cognitive-impairment-to-alzheimers-predicting-risk?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2023-08-10&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.

Early Findings Show Breast Cancer Vaccine Produces Immune Response

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine. 
- Advertisement -
×